Skip to Main Content

Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment

Conditions

Immune System

Phase III

What is the purpose of this trial?

The purpose of this study is to determine if an investigational treatment (Maribavir) is safe and effective in treating transplant recipient patients with cytomegalovirus (CMV) infections that are refractory or resistant to treatment.

  • Trial with
    Shire ViroPharma, Inc.
  • Start Date
    01/23/2018
  • End Date
    05/30/2019
Trial Image

For more information about this study, contact:

Ricarda Tomlin

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    04/09/2018
  • Study HIC
    #2000020766